2B30 Stock Overview
A biopharmaceutical company, engages in developing and commercializing therapies in Illinois. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Xeris Biopharma Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.15 |
| 52 Week High | US$4.15 |
| 52 Week Low | US$1.58 |
| Beta | 1.21 |
| 1 Month Change | 20.83% |
| 3 Month Change | 24.45% |
| 1 Year Change | 103.63% |
| 3 Year Change | 80.61% |
| 5 Year Change | n/a |
| Change since IPO | 130.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2B30 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 19.6% | -2.5% | -1.4% |
| 1Y | 103.6% | -13.2% | 15.4% |
Return vs Industry: 2B30 exceeded the German Pharmaceuticals industry which returned -13.2% over the past year.
Return vs Market: 2B30 exceeded the German Market which returned 16.8% over the past year.
Price Volatility
| 2B30 volatility | |
|---|---|
| 2B30 Average Weekly Movement | 6.8% |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 2B30 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 2B30's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 394 | John Shannon | www.xerispharma.com |
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies.
Xeris Biopharma Holdings, Inc. Fundamentals Summary
| 2B30 fundamental statistics | |
|---|---|
| Market cap | €646.67m |
| Earnings (TTM) | -€50.19m |
| Revenue (TTM) | €185.85m |
3.3x
P/S Ratio-12.3x
P/E RatioIs 2B30 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2B30 income statement (TTM) | |
|---|---|
| Revenue | US$203.07m |
| Cost of Revenue | US$36.83m |
| Gross Profit | US$166.24m |
| Other Expenses | US$221.07m |
| Earnings | -US$54.84m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.36 |
| Gross Margin | 81.86% |
| Net Profit Margin | -27.00% |
| Debt/Equity Ratio | -783.8% |
How did 2B30 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/11 22:43 |
| End of Day Share Price | 2025/03/11 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Xeris Biopharma Holdings, Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chase Knickerbocker | Craig-Hallum Capital Group LLC |
| Robin Garner Kalley | Craig-Hallum Capital Group LLC |
| Oren Livnat | H.C. Wainwright & Co. |